FTC settles with Vyera over Daraprim, Shkreli litigation to go on -Breaking
[ad_1]
© Reuters. FILE PHOTO. Martin Shkreli is a former drug company executive and arrives at U.S. District Court on the third day jury deliberations for his Securities Fraud trial. This took place in Brooklyn borough, New York City. August 2, 2017. REUTERS/Amr alfikyWASHINGTON, (Reuters) – The U.S. Federal Trade Commission reached a settlement with Vyera Pharmaceuticals regarding allegations that it tried to prevent generic versions of Daraprim from being made available. They stated in a court filing.
The filing stated that Martin Shkreli is still being sued.
Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses you may incur due to the use of these data.
Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.
[ad_2]